Grzegorz Czyżewicz

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Edward B. Garon, Tudor–Eliade Ciuleanu, Óscar Arrieta et al. · The Lancet · 2014 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +16

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

Hossein Borghaei, Scott Gettinger, Everett E. Vokes et al. · Journal of Clinical Oncology · 2021 · 661 citations · Full text

Medicine, Oncology, Pharmacology +14

Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial

Luis Paz‐Ares, Hossein Borghaei, Stephen V. Liu et al. · The Lancet · 2025 · 64 citations

Medicine, Oncology, Pharmacology +8

Decreased Levels of Histidine-Rich Glycoprotein in Advanced Lung Cancer: Association with Prothrombotic Alterations

Aleksandra Winiarska, Lech Zaręba, Grzegorz Królczyk et al. · Disease Markers · 2019 · 38 citations · Full text

Medicine, Hematology, Oncology +14

OA14.04 Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs Docetaxel in Previously Treated NSCLC

Scott Gettinger, Hossein Borghaei, Julie R. Brahmer et al. · Journal of Thoracic Oncology · 2019 · 38 citations

Medicine, Oncology, Pharmacology +9